Working with leading research institutions, Amsbio has established itself as a premier supplier of high quality Heparan Sulfate (HS) monoclonal antibodies driving breakthroughs in Glycobiology research.
Cambridge, UK, 10 April 2025: Source BioScience UK Ltd, an industry-leading provider of genomic services and histopathology diagnostics, today announced it had completed the acquisition of Cambridge Clinical Laboratories (CCL), a leading Cambridge-based provider of clinical, personalised healthcare testing services. The acquisition bolsters the Company’s clinical diagnostics portfolio by leveraging the expertise of the CCL team and new state-of-the-art clinical lab facilities at Vision Park in Cambridge, providing streamlined testing services for both preclinical and clinical research.
London, April 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for iOnctura and is pleased to announce the placement of Dr. Mark Velleca as Chair of the Board of Directors.
iOnctura is a clinical-stage precision oncology company combating neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules.
BioBeat25 13.30-18.00, Thursday 8 May at the Cambridge Union is all about getting ahead of the curve in biotech!
There are two fantastic panels on upcoming key technologies and partnering hotspots and getting to closure on investment deals.
The first on Biotech and Partnering Hotspots will explore key areas where partnerships tend to be struck and the drivers behind such deals.
Howard Group strengthens its South Cambridge science and healthcare ecosystem with latest signing
Cancer Research Horizons, the innovation arm of Cancer Research UK, has announced a collaboration with Histofy, a leader in AI-driven histopathology solutions, to develop tools that predict how colorectal cancer patients respond to different treatment options using the multi-modal S:CORT dataset.
Research and development innovation is the lifeblood of the pharmaceutical sector but in a highly competitive market returns are hard won. Our 15th annual detailed analysis, in Measuring the return from pharmaceutical innovation: Be brave, be bold, shows an upward trajectory with the IRR increasing from 4.3% in 2023 to 5.9% in 2024. This positive trend is driven largely by new high-value blockbuster assets entering the late-stage pipeline, particularly for therapies addressing obesity, menopause, Alzheimer’s, and other unmet needs.
Cambridge Opens Its Doors: A Week of Innovation at the Home of UK Life Sciences
The buzzing Cambridge Wide Open annual event returns in June, this time as a week-long interactive festival showcasing Cambridge’s pioneers, the companies of the future, and opening the offices and workspaces that make up one of the world’s most vibrant ecosystems.
Building on the momentum of the last two Cambridge Wide Open Days, the event will run from 9 - 13th June 2025, offering an immersive experience to global investors, ecosystem CEO’s and employees, sci-tech enthusiasts, policymakers, academics, and curious residents alike.
The Cortes-Ciriano group studies the mutational processes and mechanisms of genome instability underpinning tumourigenesis, immune escape, and drug response through the analysis of high-throughput sequencing data from clinical samples. The group is also leading the development of novel approaches for early cancer detection using long-read sequencing. More information about the group can be found here.
Your role